ASTRAZENECA PLC DL-,25/ GB0009895292 /
2024-04-19 1:30:33 PM | Chg. -1.050 | Volume | Bid1:56:53 PM | Ask1:56:53 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
127.350EUR | -0.82% | 1,032 Turnover: 131,182.550 |
127.650Bid Size: 400 | 127.700Ask Size: 400 | 196.51 bill.EUR | - | - |
GlobeNewswire
03-28
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...
GlobeNewswire
02-26
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
02-05
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, an...
GlobeNewswire
02-02
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patie...
GlobeNewswire
01-03
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Li...
GlobeNewswire
2023-12-26
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncol...
GlobeNewswire
2023-12-22
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023